There is reason to believe an oral therapy for Ulcerative Colitis which can involve the entire colon may be effective for Ulcerative Proctitis which involves the distal 20% or so.
See post 264131 below
IPIX is building momentum to formulate an oral formulation of Brilacidin for treatment of IBD disorders such as Ulcerative Colitis, Crohn's Disease, and Irritable Bowel Syndrome..." with expectations that a drug formulation company may be contracted in the coming weeks to begin this work."
The oral Brilacidin formulation may not be as far away as some think.
The above, of course, brings IPIX a step closer to triggering our suitor to trigger the RFR and the RFN for the additional indications.
An exciting time to be an IPIX share holder. Judging by the increased share price and volume it appears others appreciate IPIX's laying the ground work for its future.
GLTA,Farrell
January 22,2019 The planned oral Brilacidin clinical trial builds on recently released data showing in simulated gastric fluid testing very minimal degradation of Brilacidin across 4 hours, suggesting Brilacidin likely would not be subject to rapid breakdown once in the stomach. These, and other data, are informing necessary manufacturing next steps—including soliciting Requests-for-Proposals from vendors—toward developing an elegant, tailored oral dosage form of Brilacidin. As a first step, a simple oral formulation of Brilacidin, may be expediently tested in human volunteers, while the refined oral dosage form of Brilacidin is developed in parallel. The anticipated clinical study’s primary goals include assessing safety and toleration, pharmacokinetics, and the effects of Brilacidin on the gut’s microbiome.
April,7,2019 Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has implemented yield and purity enhancements in the manufacturing of Brilacidin for the bulk production of Phase 3 drug supply using the Quality by Design approach. This and other efforts associated with the chemical processes aim to achieve drug supply optimization for commercial use.
May 16/2019 The non-binding term sheet also includes a Right of First Refusal for rights to Brilacidin for the treatment of more extensive forms of Inflammatory Bowel Disease, such as Ulcerative Colitis and Crohn’s Disease, and a Right of First Negotiation for rights to Brilacidin in other Gastrointestinal (GI) indications.
May/21/2019 The Company is currently in discussions with several vendors regarding innovative advanced technologies for targeted oral delivery of Brilacidin to the colon, with expectations that a drug formulation company may be contracted in the coming weeks to begin this work.
Careful selection of an appropriate drug formulation partner should prove invaluable in expeditiously moving Brilacidin forward for diseases like UC and CD, disorders that remain in need of safe and effective options for millions of patients,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation
Market Data 
Markets 
AI
